Jones Financial Companies
RXRX icon

Jones Financial Companies’s Recursion Pharmaceuticals RXRX Stock Holding History

Jones Financial Companies’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64K Sell
21,756
-16,548
-43% -$63.9K ﹤0.01% 2854
2025
Q4 		$157K Buy
38,304
+3,986
+12% +$19.7K ﹤0.01% 2023
2025
Q3 		$162K Sell
34,318
-36,186
-51% -$190K ﹤0.01% 1869
2025
Q2 		$355K Buy
70,504
+27,376
+63% +$134K ﹤0.01% 1419
2025
Q1 		$251K Buy
43,128
+9,311
+28% +$67.9K ﹤0.01% 1403
2024
Q4 		$229K Buy
33,817
+27,016
+397% +$182K ﹤0.01% 1295
2024
Q3 		$47.5K Buy
6,801
+4,881
+254% +$35K ﹤0.01% 1659
2024
Q2 		$14.4K Buy
+1,920
New +$16.7K ﹤0.01% 1643

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jones Financial Companies's RXRX Position: Q1 2026 in Review

Jones Financial Companies reduced its Recursion Pharmaceuticals (RXRX) stake by 43% in Q1 2026, selling an estimated $63.9K and leaving 21,756 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #2854.

Jones Financial Companies first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $355K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Jones Financial Companies held 21,756 shares of Recursion Pharmaceuticals worth $64K as of Q1 2026.
  • Jones Financial Companies sold 16,548 Recursion Pharmaceuticals shares in Q1 2026, an estimated $63.9K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #2854 holding.
  • Jones Financial Companies first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Jones Financial Companies's Recursion Pharmaceuticals position peaked at $355K in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.